Compare ACADIA Pharmaceuticals Inc. (ACAD) vs e l f Beauty Inc (ELF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs e l f Beauty Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while e l f Beauty Inc trades at $74.17 (market cap $4.48B). The key difference: ACADIA Pharmaceuticals Inc. and e l f Beauty Inc are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ELF | |
|---|---|---|
Market Cap | $4.49B | $4.48B |
Sector | Health | Technology |
52-Week High | $28.06 | $146.67 |
52-Week Low | $20.06 | $49.57 |
Enterprise Value | $3.69B | $5.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ELF Beauty trades at $73.49, down 3.83% recently, but maintains a bullish technical outlook with strong support at $72. The company reported impressive earnings beats in recent quarters with Q4 2025 EPS of $1.24 beating expectations of $0.73. Revenue growth remains robust at $1.31 billion in 2025, though net margins are thin at 1.61%. Analyst sentiment is mixed with 46% buy ratings and a consensus price target of $72.82, slightly below current levels.
The stock faces valuation concerns with a high P/E of 173.68, but strong revenue growth and expansion into haircare and skincare categories provide upside potential. Key risks include tariff exposure and core brand momentum challenges. Institutional ownership trends and recent insider activity suggest cautious optimism as the company executes its diversification strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →
